Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review. (8th January 2021)

• Record Type: Journal Article
• Authors: Ajmal, Muhammad; Friedman, Jacob; Sipra, Qurat Ul Ain Riaz; Lassar, Tom
• Other Names: Garcia Victor Academic Editor.
• Is Part Of: Cardiovascular therapeutics. Volume 2021(2021)
• Publication Date: 2021-01-08
• Subjects: Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals; Cardiovascular Agents -- Periodicals; Cardiovascular Diseases -- drug therapy -- Periodicals; Agents cardiovasculaires -- Périodiques; Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques; 616.1005
• DOI: 10.1155/2021/8886210
• Languages: English
• ISSNs: 1755-5914

Abstract

Abstract : Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.